SBIR-STTR Award

Research and Screening Platform for Alzheimer's and Other Chronic Diseases
Award last edited on: 11/17/2023

Sponsored Program
SBIR
Awarding Agency
NIH : NIA
Total Award Amount
$599,334
Award Phase
2
Solicitation Topic Code
866
Principal Investigator
Alfredo A Celedon

Company Information

Scanogen Inc (AKA: Twistnostics LLC)

3102 Lord Baltimore Drive Suite 214
Baltimore, MD 21244
   (443) 640-5097
   info@scanogen.com
   www.scanogen.com
Location: Single
Congr. District: 07
County: Baltimore

Phase I

Contract Number: 1R43AG056208-01
Start Date: 5/15/2017    Completed: 4/30/2019
Phase I year
2017
Phase I Amount
$299,652
Early diagnosis of chronic diseases makes possible early treatment initiation Bloodstream miRNA panels are being pursued for screening and diagnosis of the most important chronic diseases Recently there has been a particular interest in Alzheimer s disease AD miRNA panels If successful these panels may become part of regular medical check ups However their development and application is obstructed by the poor quantitative performance and complexity of available miRNA detection techniques such as reverse transcription quantitative polymerase chain reaction RT qPCR and sequencing Here we propose the development of an accurate and simple platform for quantitative detection of miRNAs in blood that will accelerate the validation of miRNA panels and will be ideal for patient screening We will validate the new platform by studying a specific miRNA panel associated with AD We will develop a highly quantitative method to measure concentration of circulating miRNA based on direct detection without purification and without enzymatic reactions The method will be capable of highly quantitative measurements of miRNA in a variety of sample types The first aim focuses on developing a method to detect targets directly in unpurified samples The second aim focuses on optimizing the quantitative performance of the assay as well as validating the assay with clinical samples This proposal will show that the new method can dramatically simplify and improve miRNA quantification Our overall goal is to develop a powerful and flexible platform ideal for basic miRNA research and clinical diagnosis In addition the same platform will be useful to detect other targets such as messenger RNA and highly fragmented DNA with better quantitative performance faster and easier to use than alternative methods This application proposes the development of an easy to use platform for screening and early diagnosis of chronic diseases using miRNA panels with particular focus on Alzheimer s disease The new platform will be capable of quantification of miRNA in blood and other clinical samples

Phase II

Contract Number: 5R43AG056208-02
Start Date: 5/15/2017    Completed: 4/30/2019
Phase II year
2018
Phase II Amount
$299,682
Summary Early diagnosis of chronic diseases makes possible early treatment initiation. Bloodstream miRNA panels are being pursued for screening and diagnosis of the most important chronic diseases. Recently, there has been a particular interest in Alzheimer?s disease (AD) miRNA panels. If successful, these panels may become part of regular medical check-ups. However, their development and application is obstructed by the poor quantitative performance and complexity of available miRNA detection techniques such as reverse transcription quantitative polymerase chain reaction (RT-qPCR) and sequencing. Here, we propose the development of an accurate and simple platform for quantitative detection of miRNAs in blood that will accelerate the validation of miRNA panels and will be ideal for patient screening. We will validate the new platform by studying a specific miRNA panel associated with AD. We will develop a highly quantitative method to measure concentration of circulating miRNA based on direct detection, without purification and without enzymatic reactions. The method will be capable of highly quantitative measurements of miRNA in a variety of sample types. The first aim focuses on developing a method to detect 10 targets directly in unpurified samples. The second aim focuses on optimizing the quantitative performance of the assay, as well as validating the assay with clinical samples. This proposal will show that the new method can dramatically simplify and improve miRNA quantification. Our overall goal is to develop a powerful and flexible platform ideal for basic miRNA research and clinical diagnosis. In addition, the same platform will be useful to detect other targets, such as messenger-RNA and highly fragmented DNA with better quantitative performance, faster and easier to use than alternative methods.

Thesaurus Terms:
Alzheimer's Disease; Base; Biochemical Reaction; Biological Assay; Biological Markers; Blood; Blood Circulation; Cell Culture Techniques; Chronic Disease; Circulating Microrna; Clinical; Clinical Diagnosis; Code; Detection; Development; Diagnosis; Disease Diagnosis; Dna; Early Diagnosis; Early Treatment; Equipment; Flexibility; Genes; Goals; Human; Improved; Instrument; Interest; Measurement; Measures; Medical; Messenger Rna; Methods; Micrornas; Molecular; Names; Novel; Nucleotides; Patient Screening; Patients; Performance; Phase; Plasma; Polymerase Chain Reaction; Procedures; Proteins; Reaction; Reproducibility; Research; Response; Reverse Transcription; Rna; Sampling; Scanning; Screening; Single Molecule; Specimen; Techniques; Tissues; Titrations; Validation;